JO3318B1 - مثبطات bace - Google Patents

مثبطات bace

Info

Publication number
JO3318B1
JO3318B1 JOP/2014/0177A JOP20140177A JO3318B1 JO 3318 B1 JO3318 B1 JO 3318B1 JO P20140177 A JOP20140177 A JO P20140177A JO 3318 B1 JO3318 B1 JO 3318B1
Authority
JO
Jordan
Prior art keywords
bace inhibitors
bace
inhibitors
compound
pharmaceutically acceptable
Prior art date
Application number
JOP/2014/0177A
Other languages
English (en)
Inventor
James Hembre Erik
Morgan Watson Brian
James Mergott Dustin
James Green Steven
Larry Winneroski Leonard Jr
Shi Yuan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3318B1 publication Critical patent/JO3318B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم مركب بالصيغة III: حيث A هي: و Z، R1، R2، R3، وR4 هي كما تم تعريفها في هذه الوثيقة، أو ملح مقبول صيدلياً منه.
JOP/2014/0177A 2013-06-18 2014-05-29 مثبطات bace JO3318B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361836175P 2013-06-18 2013-06-18
US201361877373P 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
JO3318B1 true JO3318B1 (ar) 2019-03-13

Family

ID=51059662

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0177A JO3318B1 (ar) 2013-06-18 2014-05-29 مثبطات bace

Country Status (14)

Country Link
US (2) US9029367B2 (ar)
EP (1) EP3010925B1 (ar)
JP (1) JP2016522254A (ar)
KR (1) KR101780140B1 (ar)
CN (1) CN105324385A (ar)
AU (1) AU2014281032B2 (ar)
BR (1) BR112015029348A8 (ar)
CA (1) CA2910415C (ar)
EA (1) EA027880B1 (ar)
ES (1) ES2657905T3 (ar)
JO (1) JO3318B1 (ar)
MX (1) MX2015017156A (ar)
TW (1) TWI639607B (ar)
WO (1) WO2014204730A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
AR103680A1 (es) * 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
TW201718543A (zh) 2015-08-12 2017-06-01 Ｈ 朗德貝克公司 作爲ｂａｃｅ１抑制劑之２－胺基－３－氟－３－（氟甲基）－６－甲基－６－苯基－３，４，５，６－四氫吡啶
MA42604A (fr) * 2015-08-12 2018-06-20 H Lundbeck As 2-amino-7a-phényl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines comme inhibiteurs de bace1
TWI675034B (zh) * 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途
JP6889466B2 (ja) * 2016-12-09 2021-06-18 学校法人 名城大学 アミド基を含む単離された化合物の塩、その製造方法及びこれを用いたアミド化合物の合成方法
CN107892697B (zh) 2016-12-26 2020-11-03 郑州泰基鸿诺医药股份有限公司 一种[1,3]噻嗪-2-胺类化合物及应用，药物组合物
CN111217709A (zh) * 2018-11-27 2020-06-02 南京药石科技股份有限公司 一种（1-氟环丙基）甲胺盐酸盐的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080029965A (ko) 2005-06-14 2008-04-03 쉐링 코포레이션 아스파르틸 프로테아제 억제제
ES2572263T3 (es) 2005-10-25 2016-05-31 Shionogi & Co Derivados de dihidrooxazina y tetrahidropirimidina como inhibidores de BACE 1
EP2147914B1 (en) 2007-04-24 2014-06-04 Shionogi&Co., Ltd. Aminodihydrothiazine derivatives substituted with cyclic groups
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ES2548774T3 (es) * 2008-01-18 2015-10-20 Eisai R&D Management Co., Ltd. Derivado de aminodihidrotiazina condensado
TWI431004B (zh) * 2008-05-02 2014-03-21 Lilly Co Eli Ｂａｃｅ抑制劑
KR101324426B1 (ko) 2008-06-13 2013-10-31 시오노기세야쿠 가부시키가이샤 β 세크레타제 저해 작용을 갖는 황 함유 복소환 유도체
CA2738150A1 (en) 2008-09-30 2010-04-08 Eisai R&D Management Co., Ltd. Novel fused aminodihydrothiazine derivative
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
EP2514747A4 (en) 2009-12-09 2013-05-08 Shionogi & Co SUBSTITUTED AMINOTHIAZINE DERIVATIVE
CN102834384A (zh) 2009-12-11 2012-12-19 盐野义制药株式会社 *嗪衍生物
JPWO2011071109A1 (ja) 2009-12-11 2013-04-22 塩野義製薬株式会社 アミノ基を有する縮合ヘテロ環化合物
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
GB201100181D0 (en) 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
CN103502231A (zh) 2011-01-21 2014-01-08 卫材R&D管理有限公司 用于稠合氨基二氢噻嗪衍生物的合成的方法和化合物
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
EP2694521B1 (en) 2011-04-07 2015-11-25 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
AR086539A1 (es) 2011-05-24 2014-01-08 Bristol Myers Squibb Co COMPUESTOS PARA LA REDUCCION DE LA PRODUCCION DE b-AMILOIDE
US9073909B2 (en) 2011-06-07 2015-07-07 Hoffmann-La Roche Inc. [1,3]oxazines
UY34278A (es) 2011-08-25 2013-04-05 Novartis Ag Derivados novedosos de oxazina y su uso en el tratamiento de enfermedades
ES2605565T3 (es) 2011-08-31 2017-03-15 Pfizer Inc Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
ES2864009T3 (es) 2011-11-25 2021-10-13 Adverio Pharma Gmbh 5-Fluoro-1H-pirazolopiridinas sustituidas en forma cristalina
MX2014012683A (es) 2012-04-27 2015-01-16 Eisai R&D Man Co Ltd Metodo para producir el acido 5-(difluorometil)pirazin-2-carboxili co y un intermediario de la produccion de este.
ES2585262T3 (es) 2012-05-04 2016-10-04 Pfizer Inc Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
WO2014015125A1 (en) 2012-07-19 2014-01-23 Eisai R&D Management Co., Ltd. Fused aminodihydrothiazine derivative salts and uses thereof
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds

Also Published As

Publication number Publication date
EA027880B1 (ru) 2017-09-29
WO2014204730A1 (en) 2014-12-24
US9029367B2 (en) 2015-05-12
CA2910415A1 (en) 2014-12-24
BR112015029348A2 (pt) 2017-07-25
BR112015029348A8 (pt) 2020-03-17
AU2014281032A1 (en) 2015-11-12
CA2910415C (en) 2017-09-05
AU2014281032B2 (en) 2016-09-29
CN105324385A (zh) 2016-02-10
JP2016522254A (ja) 2016-07-28
US9169271B2 (en) 2015-10-27
EA201592183A1 (ru) 2016-05-31
ES2657905T3 (es) 2018-03-07
KR20160009052A (ko) 2016-01-25
MX2015017156A (es) 2016-03-16
US20140371212A1 (en) 2014-12-18
EP3010925A1 (en) 2016-04-27
TWI639607B (zh) 2018-11-01
EP3010925B1 (en) 2017-10-04
TW201536793A (zh) 2015-10-01
KR101780140B1 (ko) 2017-09-19
US20150210716A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12018500343A1 (en) Heterocyclic amides as kinase inhibitors
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
JO3318B1 (ar) مثبطات bace
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
IN2015DN00598A (ar)
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
RS54730B1 (sr) Inhibitori beta sekretaze
MX368178B (es) Compuestos de ácido dimetilbenzoico.
MX2015012629A (es) Compuestos de imidazo piridina.
EA201690894A1 (ru) Феноксиэтилы
MX2015015841A (es) Compuestos de fenoxietil dihidro-1h-isoquinolina.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2015007309A (es) Derivado de hidantoina.
PH12015502462A1 (en) Imidazo-triazine derivatives as pde10 inhibitors
MX359399B (es) Inhibidores de 17alfa-hidroxilasa/c17-20-liasa.
MX2016006807A (es) Derivados de imidazol.
PH12016500809A1 (en) Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors
IN2012DE00110A (ar)
MX2015009377A (es) Compuestos radiomarcados.